Angiex is a biotherapeutics company specializing in vascular-targeted treatments with a focus on angiogenesis. Founded by world-class scientists, Angiex aims to exploit novel biology to gain revolutionary power over cancer. The company is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality. Angiex's core mission is that no one should die of cancer, reflecting their commitment to finding solutions for this pervasive health issue.
Angiex has made significant strides in the field of oncology through its innovative approach to drug development. By targeting fundamental aspects of endothelial biology, the company has positioned itself at the forefront of cancer treatment research. Their pioneering work on ND-ADCs has the potential to revolutionize how cancer is treated, offering new hope to millions affected by the disease annually.
